Targeting circadian-clock genes may offer therapeutic benefits for enhancing resistance to insulin resistance, diabetes, obesity, metabolic syndrome, and atherosclerosis (78). The gene discussed is CLOCK; the disease is obesity due to melanocortin 4 receptor deficiency.